Annals of Oncology 4:533-543, 1993
© 1993 European Society for Medical Oncology
review-article |
DNA topoisomerase I and II as targets for rational design of new anticancer drugs
Imperial Cancer Research Fund, Medical Oncology Unit Western General Hospital, Edinburgh, United Kingdom
Correspondence to: Jeffrey Cummings, Ph.D., Imperial Cancer Research Fund, Medical Oncology Unit, Western General Hospital, Edinburgh EH4 2XU, U.K.
BACKGROUND:: Topoisomerase I and II (topo I and II) are enzymes which alter the topological state of DNA through DNA strand cleavage, strand passage and religation. They participate in most aspects of DNA metabolism and are therefore vital to the cell undergoing division. Only one form of topo I has been identified whereas two isoenzymes of topo II have been described: the 
form (170 kDa protein) and ß form (180 kDa protein). Both topo II isoenzymes have distinct nuclear localisation, are regulated independently, differ in their responsiveness to inhibitors and are differentially expressed in drug resistant cell lines.
RESULTS:: Several clinically active anticancer drugs (e.g., doxorubicin, m-AMSA, VP-16 and camptothecins) poison these enzymes by stabilizing a putative reaction intermediate called the cleavable complex (cc) where the topoisomerase remains covalently attached to either one strand of DNA (topo I) or both strands of double helix (topo II) after strand cleavage. DNA cleavage sites appear unique for different classes of inhibitor, and are probably critical for defining cytotoxicity. Formation of the cc may cause cell death either by colliding with replication forks, by promoting illegitimate genomic-DNA recombination, by arresting cells in the G2-phase of the cell cycle or by inducing apoptosis.
CONCLUSION:: New classes of inhibitor have recently been described with novel mechanisms of action including compounds which do not stabilize cleavable complexes or bind significantly to DNA. These may prove to be more selective and less toxic. They may also avoid the possible problem of therapy-related leukemias associated with topo inhibitors which induce DNA cleavage and chromosomal aberrations.
topoisomerases, molecular biology, mechanism of inhibition, cleavable complexes, novel inhibitors, drug resistance, rational design, new agents
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  Y. M. KANAAN, J. R. DAS, O. BAKARE, N. M. ENWEREM, S. BERHE, D. BEYENE, V. WILLIAMS, Y. ZHOU, and R. L. COPELAND Jr. Biological Evaluation of 2,3-Dichloro-5,8-Dimethoxy-1,4-Naphthoquinone as an Anti-breast Cancer Agent Anticancer Res, January 1, 2009; 29(1): 191 - 199. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Toyoda, S. Kagaya, I. G. Cowell, A. Kurosawa, K. Kamoshita, K. Nishikawa, S. Iiizumi, H. Koyama, C. A. Austin, and N. Adachi NK314, a Topoisomerase II Inhibitor That Specifically Targets the {alpha} Isoform J. Biol. Chem., August 29, 2008; 283(35): 23711 - 23720. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Lonning, S Knappskog, V Staalesen, R Chrisanthar, and J. Lillehaug Breast cancer prognostication and prediction in the postgenomic era Ann. Onc., August 1, 2007; 18(8): 1293 - 1306. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Knoop, H. Knudsen, E. Balslev, B. B. Rasmussen, J. Overgaard, K. V. Nielsen, A. Schonau, K. Gunnarsdottir, K. E. Olsen, H. Mouridsen, et al. Retrospective Analysis of Topoisomerase IIa Amplifications and Deletions As Predictive Markers in Primary Breast Cancer Patients Randomly Assigned to Cyclophosphamide, Methotrexate, and Fluorouracil or Cyclophosphamide, Epirubicin, and Fluorouracil: Danish Breast Cancer Cooperative Group J. Clin. Oncol., October 20, 2005; 23(30): 7483 - 7490. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Sampath, P. R. Long, R. L. Shepard, X. Xia, V. Devanarayan, G. E. Sandusky, W. L. Perry III, A. H. Dantzig, M. Williamson, M. Rolfe, et al. Human SPF45, a Splicing Factor, Has Limited Expression in Normal Tissues, Is Overexpressed in Many Tumors, and Can Confer a Multidrug-Resistant Phenotype to Cells Am. J. Pathol., November 1, 2003; 163(5): 1781 - 1790. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Merchant, K. Tutsch, A. Dresen, R. Arzoomanian, D. Alberti, C. Feierabend, K. Binger, R. Marnoccha, J. Thomas, J. Cleary, et al. Phase I Clinical and Pharmacokinetic Study of NSC 655649, a Rebeccamycin Analogue, Given in Both Single-Dose and Multiple-Dose Formats Clin. Cancer Res., July 1, 2002; 8(7): 2193 - 2201. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-Y. Douillard Irinotecan: a new treatment in metastatic colorectal cancer Journal of Oncology Pharmacy Practice, September 1, 2000; 6(3_suppl): S3 - S9. [Abstract] [PDF]
|
|
|
|
 |
|
 R. Sanchez-Prieto, J. M. Rojas, Y. Taya, and J. S. Gutkind A Role for the p38 Mitogen-activated Protein Kinase Pathway in the Transcriptional Activation of p53 on Genotoxic Stress by Chemotherapeutic Agents Cancer Res., May 1, 2000; 60(9): 2464 - 2472. [Abstract] [Full Text]
|
|
|
|
 |
|
 G. Bicknell, R. Snowden, and G. Cohen Formation of high molecular mass DNA fragments is a marker of apoptosis in the human leukaemic cell line, U937 J. Cell Sci., January 9, 1994; 107(9): 2483 - 2489. [Abstract] [PDF]
|
|